In contrast to most other adipokines, the blood plasma level of adiponectin is lower during obesity and during the related pathologies, including CVDs, T2DM, and nonalcoholic fatty liver disease (NAFLD) [36,37,38]. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.